Dairy Products and Metabolic Risk Factors: How Much Do We Know?

Less than a decade ago, epidemiological research classified high-fat dairy products as integral to a “Western” dietary pattern that was associated with an increased risk for developing type 2 diabetes (1). Animal fat, including that found in whole milk and high-fat dairy products, was thought to be the pathogenic factor with little consideration of the composition of milk fat, which has the potential opposite effects of various fatty acids (saturated fatty acids, trans fatty acids, and conjugated linoleic acid) (2).

The study by Fumeron et al. (3) in this issue of Diabetes Care found an inverse relationship between intake of dairy products and incident diabetes and several cardiometabolic risk factors in the French DESIR (Data from the Epidemiological Study on the Insulin Resistance Syndrome) study. A limitation of the DESIR analysis is the homogeneity of the French study population. Generalizing the study finding to more diverse population groups, especially populations of color with disparate rates of diabetes, may not be appropriate. However, the DESIR findings are consistent with a number of recent epidemiological studies that have also reported an inverse relationship between intake of dairy products or nutrients in dairy products and the risk of developing obesity-related chronic diseases including diabetes in a variety of population groups (4–13).

Much of the early interest in dairy intake focused on its mineral content in relation to blood pressure. Although calcium is the nutrient most often associated with dairy products, a broader view of the mineral content is needed. Dairy products provide magnesium and potassium to the dietary intake as well as calcium. Although the effects of dairy products on the reduction in blood pressure may be related to the balance of these minerals (11,14), mineral supplementation trials found little benefit (15,16).

Trying to examine why dairy products may reduce diabetes risk is fraught with difficulty. Examination of dairy intake in relation to obesity, diabetes, and cardiometabolic risk requires consideration of a wide range of nutrients. Although vitamin D has been postulated to reduce diabetes risk and convey cardiometabolic benefit, the evidence base is weak (17). Furthermore, the DESIR food frequency questionnaire is not structured to provide vitamin D values for exploration of the relationship. For example, the role of dairy protein also needs to be considered (18). Trying to extrapolate from observational data, in which dairy products are associated with lower risk, to food or nutrient recommendations is extremely challenging.

Dairy products have long been integral to federal dietary recommendations, but current recommendations are based on evidence from the Dietary Approaches to Stop Hypertension (DASH) study, which evaluated the blood pressure and other health outcomes of a dietary pattern containing low-fat dairy foods (three servings) (19). The DASH dietary pattern is highlighted in the 2010 Dietary Guidelines and has potential cardiometabolic benefits beyond reducing blood pressure (20–22). A literature search yielded no articles that examined the relative contribution of dairy products of the DASH dietary pattern to the effects on blood pressure or other cardiometabolic risk factors.

Although the DASH dietary pattern only contains low-fat dairy products, the French DESIR and other epidemiological studies suggest that intake of full fat as well as low-fat dairy products may reduce diabetes risk and provide cardiometabolic benefits. These findings raise questions about the role of fatty acids in dairy products. Biomarkers related to dairy intake as well as metabolic biomarkers may provide insights to explain the observational data.

Biomarkers related to fatty acid intake are of particular interest as research has suggested that the tertiary structure and shape of saturated fatty acids (SFA) affects their biological function (23). Exposure of pancreatic β-cells to long-chain SFA can affect their function by what has been termed endoplasmic reticulum (ER) stress, which can ultimately lead to cell death. This process is thought to play a role in the development of type 2 diabetes via a decrease in β-cell mass. Research using a yeast-based model has examined many features of lipotoxicity in human cells, to screen fatty acids of various structures for their capacity to counter ER stress. Findings from this research suggest that the tendency of a fatty acid to reduce SFA toxicity depends on a complex conjunction of parameters, including chain length, level of unsaturation, position of the double-bonds, and the nature of the isomers (cis or trans). As building blocks for phospholipid synthesis, fatty acids help regulate cell membrane organization and ER function of the β-cell.

Examination of the role of dairy products in obesity should consider the effects of fatty acids in dairy products on insulin resistance and diabetes-related risk. Ruminant animals, such as cows, sheep and goats synthesize both cis and trans isomers for the monounsaturated fatty acids of fatty acids with chain lengths of 14 to 18 carbons. Trans-palmitoleic acid (also known as trans-palmitoleate) is a 16 carbon trans fatty acid found in the milk produced by ruminant animals. Recently published research has reported that higher levels of circulating trans-palmitoleate were associated with lower levels of insulin resistance, dyslipidemia, and incident diabetes in a 14-year follow-up of adults in the Cardiovascular Health Study (24).

Research suggesting that intake of dairy products is associated with lower risk of diabetes is intriguing. However, a note of caution is needed to avoid jumping on a treatment bandwagon based on epidemiological data without evidence of benefit from well-controlled clinical trials (25). When dietary patterns are associated with lower disease risk, the shortcut approach for a quick fix that focuses on nutrient supplementation can be ill advised.

Judith Wylie-Rosett, EDD, RD

From the Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.

Corresponding author: Judith Wylie-Rosett, judith.wylie-rosett@einstein.yu.edu.
were reported.

References

1. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002;136:201–209
2. Schrezenmeir J, Jagla A. Milk and diabetes. J Am Coll Nutr 2000;19(Suppl):176S–190S
3. Fumeron F, Lamri A, Abi Khalil C, et al.; the Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Study Group. Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a French prospective study. Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2011;34:813–817
4. Major GC, Chaput JP, Ledoux M, et al. Recent developments in calcium-related obesity research. Obes Rev 2008;9:428–445
5. Snijder MB, van Dam RM, Stehouwer CD, Hiddink GJ, Heine RJ, Dekker JM. A prospective study of dairy consumption in relation to changes in metabolic risk factors: the Hoorrn Study. Obesity (Silver Spring) 2008;16:706–709
6. Baxter AJ, Coyne T, McClintock C. Dietary patterns and metabolic syndrome—a review of epidemiologic evidence. Asia Pac J Clin Nutr 2006;15:134–142
7. Dixon LB, Pellizzon MA, Jawad AF, Tershakovec AM. Calcium and dairy intake and measures of obesity in hyper- and normocholesterolemic children. Obes Res 2005;13:1727–1738
8. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi F. Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. Am J Clin Nutr 2005;82:523–530
9. Huang TT, McCrory MA. Dairy intake, obesity, and metabolic health in children and adolescents: knowledge and gaps. Nutr Rev 2005;63:71–80
10. Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 2002;287:2081–2089
11. Ma B, Lawson AB, Liese AD, Bell RA, Mayer-Davis EJ. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. Am J Epidemiol 2006;164:449–458
12. Liu S, Choi HK, Ford E, et al. A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care 2006;29:1579–1584
13. Harkness LS, Bonny AE. Calcium and vitamin D status in the adolescent: key roles for bone, body weight, glucose tolerance, and estrogen biosynthesis. J Pediatr Adolesc Gynecol 2005;18:305–311
14. Massey LK. Dairy food consumption, blood pressure and stroke. J Nutr 2001;131:1875–1878
15. Sacks FM, Brown LE, Appel L, Borhani NO, Evans D, Whelton P. Combinations of potassium, calcium, and magnesium supplements in hypertension. Hypertension 1999;26:925–936
16. Yamamoto ME, Applegate WB, Klag MJ, et al., Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Lack of blood pressure effect with calcium and magnesium supplementation in adults with high-normal blood pressure. Results from Phase I of the Trials of Hypertension Prevention (TOHP). Ann Epidemiol 1995;5:96–107
17. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiovascular outcomes. Ann Intern Med 2010;152:307–314
18. Wylie-Rosett J, Isasi CR. Considering options for attenuating postmeal glucose excursions. Diabetes Care 2010;33:2709–2710
19. Jarvis JK, Miller GD. Overcoming the barrier of lactose intolerance to reduce health disparities. J Natl Med Assoc 2002;94:55–66
20. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999;159:285–293
21. Appel LJ, Moore TJ, Obarzanek E, et al; DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117–1124
22. Chen ST, Maruthur NM, Appel LJ. The effect of dietary patterns on estimated coronary heart disease risk: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Circ Cardiovasc Qual Outcomes 2010;3:484–489
23. Deguil J, Pineau L, Rowland Snyder EC, et al. Modulation of lipid-induced ER stress by fatty acid shape. Traffic 2011;12:349–362
24. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 2010;153:790–799
25. Prentice RL. Clinical trials and observational studies to assess the chronic disease benefits and risks of multivitamin-multimineral supplements. Am J Clin Nutr 2007;85 (Suppl. 1):3085–3135